ORIGINAL ARTICLE: Recurrent Pregnancy Loss and Frequency of Eight Antiphospholipid Antibodies and Genetic Thrombophilic Factors in Czech Women (original) (raw)
Related papers
Role of antiphospholipid antibodies in recurrent pregnancy loss
International journal of clinical obstetrics and gynaecology, 2020
Antiphospholipid syndrome is associated with a hallmark of Obstetric complications including recurrent miscarriage, early delivery, oligohydramnios, prematurity, intrauterine growth restriction, fetal distress, fetal or neonatal thrombosis, pre-eclampsia/eclampsia, HELLP syndrome, arterial or venous thrombosis and placental insufficiency. Antiphospholipid antibodies promote activation of endothelial cells, monocytes and platelets, causing an overproduction of tissue factor and thromboxane A2. These factors lead to a hypercoagable state leading to various obstetric complications. The aim of this study was to evaluate the prevalence of anti-phospholipid antibodies in patients with RPL and to evaluate the relation of antibody positivity with other parameters.
European Journal of Obstetrics & Gynecology and Reproductive Biology, 2005
Objective: We assessed the prevalence of inherited (FV-Leiden and PRT G20210A), and acquired (anti-PL antibodies) risk factors among habitual aborters in Tunisia. Study design: We studied prospectively 146 patients with !3 consecutive early, late, or early-late recurrent pregnancy losses, together with 99 age-matched controls. Anticardiolipin antibodies (ACL), lupus anticoagulant (LA), and APC resistance (APCR) were detected by ELISA, dilute Russell Viper Venom Time (dRVVT), and coagulation tests, respectively, and FV-Leiden and PRT G20210A genotypes were assessed by PCR. Results: Anti-PL antibody frequencies were 45 and 9% among patients and controls, respectively (P < 0.001), with positive LA only (P = 0.004), or combined elevated ACL-positive LA being consistently higher (P < 0.001) among patients than controls. FV-Leiden (20.54% versus 6.06%), but not PRT G20210A (2.74% versus 4.04%) was significantly higher in patients versus controls. Among LA-positive cases higher prevalence of G/A (14/146 versus 1/99) and A/A genotypes (4/146 versus 0/99) were seen, and among ACL-positive cases higher prevalence of G/A (10/146 versus 0/99) and A/A genotypes (2/146 versus 0/99) were recorded. Conclusions: Anti-PL antibodies and FV-Leiden, but not PRT G20210A, are associated with recurrent idiopathic pregnancy losses in Tunisian women.
Clinical immunology Bouquet variety of antiphospholipid antibodies in recurrent pregnancy loss
Central European Journal of Immunology, 2014
seventy-six female patients with two or more recurrent pregnancy losses (rPl) during the 1 st trimester were studied. Based on the results of the aCl and aB2gPi antibodies testing, patients were divided in two groups: 22 patients with rPl and elevated immunoglobulin (ig) g/igM aCl and/or aB2gPi [rPl + antiphospholipid syndrome (aPs)] and 54 patients with rPl alone (without high antibodies). immunoglobulin g aPs and igg a-anv in patients with rPl + aPs were higher than in controls and igg aPs were higher in rPl + aPs than in rPl alone. additionally igg a-anv and igM aPe are higher in rPl alone than in controls. in 18/22 (81%) patients with rPl + aPs and 29/54 (54%) patients with rPl alone, there were one or more positive antibodies: aPs, aPt, a-anv or aPe. these results raise a question whether or not these antiphospholipid antibodies should be routinely tested in women with RPL and especially in the context of the so-called "seronegative APS".
Antiphospholipid antibodies and the investigation of recurrent miscarriage
Current Obstetrics & Gynaecology, 1999
Recurrent miscarriage (three or more consecutive miscarriages) affects 1% of the female population and this causes severe psychological morbidity in both the sufferer and their partner. For many years the aetiology of recurrent miscarriage in the majority of cases has remained unclear. Treatment regimens to improve pregnancy outcome were based on poorly-designed studies, often without control cohorts, which have subsequently been shown to be of no proven benefit. Over the past 15 years accumulating evidence has implicated the presence of antiphospholipid antibodies (APAbs) in the aetiology of recurrent miscarriage. APAbs can be found in 15% of the recurrent miscarriage population, and are associated with first and second-trimester miscarriages as well as other obstetric complications. Aspirin and subcutaneous heparin administration are of clinically-proven benefit in lowering the miscarriage rate in women with this condition. Maternal side effects of aspirin and heparin are rare but include thrombocytopenia and osteoporosis. No direct teratogenic effects of aspirin and heparin have been demonstrated but pregnancies complicated by APAbs need to be monitored closely for evidence of pre-eclampsia and intrauterine growth restriction.
Human Reproduction, 2002
Recurrent pregnancy loss (RPL) has been associated with antiphospholipid antibodies (APA) including anticardiolipin and lupus anticoagulant. Therapy using heparin and aspirin has been shown to significantly improve the live birth rate. We evaluated whether other APA should be considered as a basis for treatment in women with RPL. We also assessed the efficacy of heparin and aspirin therapy compared with aspirin alone in these women. A two-centred, prospective, cohort evaluation of 79 women with two or more consecutive pregnancy losses who underwent a complete evaluation for RPL that was negative except for positive APA. Women with RPL and APA to cardiolipin (CL), phosphatidyl serine (PS) and/or lupus anticoagulant (LAC) treated with heparin and aspirin (group 1) were compared with those with other positive APA (to phosphatidyl inositol, phosphatidyl glycerol and/or phosphatidyl ethanolamine) treated with heparin or aspirin (group 2) or treated with aspirin alone (group 3). There were no significant differences in patients&amp;#39; demographics between groups. There were 19 viable infants born to 25 women (76%) in group 1, 18 viable infants born to the 28 women (64%) in group 2, and 12 viable infants born to the 26 women (46%) in group 3. Only the comparison between group 1 and group 3 reached statistical significance (P = 0.03). APA other than CL, PS and LAC may be associated with RPL.
BMC Pregnancy and Childbirth, 2023
Background Multiple etiologies contribute to recurrent pregnancy loss (RPL) including immunological, endocrine, anatomical, genetic and infection but more than 50% of cases remain unexplained. Evidences of thrombotic and inflammatory processes were observed at maternal-fetal interface and considered pathological findings in most RPL cases including unexplained cases. This study aimed to evaluate the association between RPL and several risk factors: platelet parameters, coagulation factors, antiphospholipid syndrome, and thyroid function. Methods This is an unmatched case-control study that included 100 RPL and 100 control women. Anthropometric and health data were collected and a gynecologist examined participants to assure fitting the inclusion criteria. Platelet parameters [including Mean Platelet Mass (MPM), Concentration (MPC) and Volume (MPV)] and ratios (MPV/ Platelet, MPC/Platelet, MPM/Platelet, Platelet/Mononuclear cells), coagulation markers [Protein C (PC), Protein S (PS), Antithrombin III, D-dimer], antiphospholipid antibodies [Anti-phospholipid (APA), Anti-cardiolipin (ACA) and anti-B2glycoprotein 1], Lupus anticoagulant, Antinuclear antibodies, and thyroid function (Thyroid stimulating hormone and anti-thyroid peroxidase) were measured. Results Mean ages of cases and controls at marriage were 22.5 years for both, and their current ages were 29.4 and 33.0, respectively. 92% of cases and 99% of controls aged blow 30 years at marriage. 75% of cases have 3-4 miscarriages and 9% have ≥ 7 miscarriages. Our results indicated significantly lower male/female age ratio (p = .019), PC (p = .036) and PS (p = .025) in cases compared to controls. Plasma D-dimer (p = .020) and antiphospholipid antibodies [ACA (IgM and IgG), APA (IgM)] were significantly higher in cases compared to controls. No significant differences were observed between cases and controls concerning APA (IgG), anti-B2-glycoprotein 1 (IgM and IgG),
Role of Antiphospholipid Antibody in Early Pregnancy Loss
International Journal of Pharma Research and Health Sciences, 2015
Aim & objective- To detect correlation between antiphospholipid antibodies in early pregnancy losses.Material & Method-In this study70 patients were taken from the department of obstetrics and gynaecology of M.L.B. Medical College , Jhansi in year 2013. Patients were investigated for antiphospholipid antibodies and lupus anticoagulant after complete history, examination and investigation of recurrent pregnancy loss.Patients were divided in two groups.Group-1: Patients having history of 2 or more abortions. (Study group)Group-2: Patients having normal obstetrical history. (Control group)Results-Majority of patients study group were in range of 20-25 year age group. Majority of abortions (68.89%) occurred during 1sttrimester.Positive test for antiphospholipid was 6.67% (3 patients) in study group while none was positive in control group (P=<.001%). Majority of positive patients were positive for anticardiolipin antibody. Conclusion-Antiphospholipid antibodies have a definite role in earlypregnancy loss.